| Project/Area Number |
01880022
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
代謝生物化学
|
|---|
| Research Institution | Tokushima University |
|---|
Principal Investigator |
HIGUCHI Tomihiko Tokushima University, Pharmaceutical Sciences, Associate Professor, 薬学部, 助教授 (50035557)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YANAGI Yoshikazu Sumitomo Pharmaceutical CO. LTD., Developmental Section of Medical Ddrugs, Head, 医薬開発部, 部長
|
|---|
| Project Period (FY) |
1989 – 1991
|
| Project Status |
Completed (Fiscal Year 1991)
|
| Budget Amount *help |
¥28,100,000 (Direct Cost: ¥28,100,000)
Fiscal Year 1991: ¥9,300,000 (Direct Cost: ¥9,300,000)
Fiscal Year 1990: ¥9,300,000 (Direct Cost: ¥9,300,000)
Fiscal Year 1989: ¥9,500,000 (Direct Cost: ¥9,500,000)
|
|---|
| Keywords | Anticancer drug / Selective toxicity / Mitochondria / Anisotropic inhibitor / Cisplatin / Human brease cancer (MX-1) / 癌診断薬 / Sarcoma180 / 白血病由来細胞(P388) |
|---|
| Research Abstract |
1. We found that 20 species of the anisotropic inhibitors of energy transductionin mitochondria, which are membrane-side specific inhibitors in mitochondrial inner membrane, had a lethal effect on both exponentially growl and, stationary phases of P388 and Sarcoma 180 cancer cells.
2. TZ3-4 and TZ3-13 had a dramatical effect on decreasing Sarcoma 180 transplanted into mice.
3. We developed a preparation method of intact mitochondria from human breast cancer (MX-1).
4. We demonstrated that cisplatin selectively inhibited the respiration in mitochondria prepared from human breast cancer (MX-1), but not those activities in mitochondria prepared from normal rat liver and heart.
The present findings indicate an extremely important possibility of development of selective toxic anticancer drug targeting human breast cancer'mitochondria.
|
